Skip to main content

Advertisement

Table 1 Baseline Demographic and Disease Characteristics for Patients Who Provided BPI-SF or RSCL at Baseline

From: Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer

  BPI-SF patients RSCL patients
Number of patients with baseline assessment 286 336
Age, median (range) 55 (27–83) 54 (27–83)
Age ≥ 65 years (n, %) 56 (19.6) 59 (17.6)
Ethnicity, n (%)
 Caucasian 202 (70.6) 220 (65.5)
 Asian 15 (5.2) 16 (4.8)
 Hispanic 55 (19.2) 86 (25.6)
 Other 14 (4.9) 14 (4.2)
Stage at entry (n, %)
 Unresectable 14 (4.9) 15 (4.5)
 Metastatic 272 (95.1) 321 (95.5)
Karnofsky Performance Status (n, %)
  < 90 75 (26.2) 86 (25.6)
 90 or 100 210 (73.4) 249 (74.1)
 Unknown 1 (0.3) 1 (0.3)
Tumor metastatic site (n, %)
 Visceral 213 (74.5) 251 (74.7)
 Non-visceral only 73 (25.5) 85 (25.3)
Menopausal status
 Peri-menopausal 10 (3.6) 12 (3.6)
 Post-menopausal 237 (84.3) 277 (83.7)
 Pre-menopausal 34 (12.1) 42 (12.7)
 Unknown 5 (1.7) 5 (1.5)
Estrogen receptor status (n, %)
 Positive 117 (40.9) 133 (39.6)
 Negative 120 (42.0) 141 (42.0)
 Unknown 49 (17.1) 62 (18.5)
Progesterone receptor status
 Positive 101 (35.3) 113 (33.6)
 Negative 123 (43.0) 146 (43.5)
 Unknown 62 (21.7) 77 (22.9)
Pathologic diagnosis
 Ductal breast carcinoma 228 (79.7) 276 (82.1)
 Non-ductal breast carcinoma 58 (20.3) 60 (17.9)
Basis for pathologic diagnosis
 Histopathological 257 (89.9) 303 (90.2)
 Cytological 29 (10.1) 33 (9.8)
Prior radiotherapy
 Yes 196 (68.5) 238 (70.8)
 No 90 (31.5) 98 (29.2)
Prior hormone therapy
 Yes 151 (52.8) 164 (48.8)
 No 135 (47.2) 172 (51.2)
  1. BPI-SF Brief Pain Inventory-Short Form, RSCL Rotterdam Symptom Checklist